Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-978 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| EDP-978 SAD Cohorts | EXPERIMENTAL | EDP-978 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, Dose 6 and Dose 7, orally daily in one single administration |
| EDP-978 MAD Cohorts | EXPERIMENTAL | EDP-978 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily for 14 days |
| EDP-978 SAD Placebo Cohorts | PLACEBO_COMPARATOR | Matching placebo, orally, once daily in one single administration |
| EDP-978 MAD Placebo Cohorts | PLACEBO_COMPARATOR | Matching placebo, orally, once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| EDP-978 | DRUG | Oral administration |
| Placebo | DRUG | Placebo to match EDP-978, oral administration |
Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive. Exclusion Criteria: * Clinically relevant evidence or history of illness or disease. * Infection with human i...
EDP-978 is an investigational small molecule being developed for chronic inducible urticaria, a type of chronic hives triggered by specific physical stimuli. It is also being studied in chronic spontaneous urticaria. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
EDP-978 is a small molecule, but its specific molecular target has not been disclosed. The drug is being investigated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults, with the goal of treating chronic inducible urticaria and chronic spontaneous urticaria.
EDP-978 is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ENTA. The company is conducting a Phase 1 clinical trial of EDP-978 in the United States.
EDP-978 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting healthy adult volunteers to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics.
EDP-978 is being studied in a Phase 1 clinical trial with the identifier NCT07540910. This randomized, double-blind, placebo-controlled trial is investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of EDP-978 in healthy adults. The trial is recruiting participants in the United States.
EDP-978 is a distinct investigational drug candidate developed by Enanta Pharmaceuticals. No alternative names for EDP-978 have been disclosed. It is being studied specifically for chronic inducible urticaria and chronic spontaneous urticaria.